Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study-Reference-Cited by-同舟云学术

Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study

Published:2013-11-24 Issue:5 Volume:32 Page:1331-1338
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Ploussard Guillaume, ,Staerman Frédéric,Pierrevelcin Jean,Larue Sébastien,Villers Arnauld,Ouzzane Adil,Bastide Cyrille,Gaschignard Nicolas,Buge François,Pfister Christian,Bonniol Romain,Rebillard Xavier,Fadli Saad,Mottet Nicolas,Saint Fabien,Saad Rodrigue,Beauval Jean-Baptiste,Roupret Morgan,Audenet François,Peyromaure Mickaël,Delongchamps Nicolas Barry,Vincendeau Sébastien,Fardoun Tarek,Rigaud Jérôme,Soulie Michel,Salomon Laurent

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://link.springer.com/content/pdf/10.1007/s00345-013-1214-0.pdf

Reference28 articles.

1. Doherty AP, Bower M, Smith GL et al (2000) Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br J Cancer 83:1432–1436

2. Shen S, Lepor H, Yaffee R, Taneja SS (2005) Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 173:777–780

3. Sengupta S, Blute ML, Bagniewski SM et al (2006) Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival. J Urol 175:1684–1690

4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591–1597

5. Rogers CG, Khan MA, Craig Miller M, Veltri RW, Partin AW (2004) Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy. Cancer 101:2549–2556

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent;European Urology;2024-08

2. Predictive factors for disease progression after salvage radiation therapy in biochemical recurrent patients treated by radical prostatectomy;Prostate International;2023-09

3. French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease;Progrès en Urologie;2022-11

4. Stereotactic Radiotherapy after Radical Prostatectomy in Patients with Prostate Cancer in the Adjuvant or Salvage Setting: A Systematic Review;Cancers;2022-01-29

5. Management of patients with a persistently elevated PSA after radical prostatectomy: a narrative review;World Journal of Urology;2022-01-13